However, it has also been reported that only the expression of pVEGFR2 in tumor tissues can predict the clinical benefit and progression-free survival of breast cancer patients receiving apatinib and VEGF or sVEGFR2 in serum cannot accurately predict the prognosis of patients [7]. Here, VEGFA is linked to breast carcinoma.